Mg2+ dependence of Ca2+ release from the sarcoplasmic reticulum induced by sevoflurane or halothane in skeletal muscle from humans susceptible to malignant hyperthermia

British Journal of Anaesthesia

Volumn 97, Issue 3, 2006, Pages 320-328

  Duke, A M ^a   Hopkins, P M ^b   Halsall, P J ^b   Steele, D S ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Anaesthetics volatile, halothane; Anaesthetics volatile, sevoflurane; Complications, malignant hyperthermia; Mg2+; Muscle cardiac, sarcoplasm reticulum

Indexed keywords

CALCIUM ION; FURA 2; HALOTHANE; MAGNESIUM ION; SEVOFLURANE; CALCIUM; ETHER DERIVATIVE; INHALATION ANESTHETIC AGENT; MAGNESIUM;

ARTICLE; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DISEASE SEVERITY; DRUG POTENCY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN TISSUE; HYPOMAGNESEMIA; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; PRIORITY JOURNAL; PROBABILITY; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE; VASTUS MEDIALIS MUSCLE; DRUG EFFECT; METABOLISM; MUSCLE CELL; PHYSIOLOGY; TISSUE CULTURE TECHNIQUE;

ANESTHETICS, INHALATION; CALCIUM; CYTOSOL; HALOTHANE; HUMANS; MAGNESIUM; MALIGNANT HYPERTHERMIA; METHYL ETHERS; MUSCLE FIBERS; SARCOPLASMIC RETICULUM; TISSUE CULTURE TECHNIQUES;

EID: 33748054498     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/ael179     Document Type: Article

References (36)

1. 2+ regulation defects. Physiol Rev 1996; 76: 537-92
2. Sambuughin N, Sei Y, Gallagher KL, et al. North American malignant hyperthermia population: Screening of the ryanodine receptor gene, identification of novel mutations. Anesthesiology 2001; 95: 594-9
3. Robinson RL, Anetseder MJ, Brancadoro V, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: How confident can we be of genetic testing? Eur J Hum Genet 2003; 11: 342-8
4. 2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J Biol Chem 1997; 272: 26332-9
5. 2+ release from the sarcoplasmic reticulum in skeletal muscle from humans susceptible to malignant hyperthermia. Anesthesiology 2004; 101: 1339-46
6. 2+ releasing action of caffeine and depolarisation in skeletal muscle fibres of the rat. J Physiol 2001; 531: 715-28
7. 2+ release channels in malignant hyperthermia. Biophys J 1997; 73: 1913-24
8. Yang T, Ta TA, Pessah IN, Allen PD. Functional defects in six ryanodine receptor isoform-1 (RyRI) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. J Biol Chem 2003; 278: 25722-30
9. 2+ release in skeletal muscle from humans susceptible to malignant hyperthermia. J Physiol 2002; 544: 85-95
10. 2+ release from the sarcoplasmic reticulum in rat skeletal muscle. J Physiol 2003; 551: 447-54
11. 2+ release in muscle fibres of pigs susceptible to malignant hyperthermia. Am J Physiol 1997; 272: 203-11
12. Harrison SM, Robinson M, Davies LA, Hopkins PM, Boyett MR. Mechanisms underlying the inotropic action of halothane on intact rat ventricular myocytes. Br J Anaesth 1999; 82: 609-21
13. 2+ contribute to the inotropic effects of sevoflurane in rat ventricle. Br J Anaesth 2005; 94: 279-86
14. The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56: 1267-9
15. Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41: 955-66
16. 2+. J Physiol 1990; 420: 337-53
17. 2+ regulation by the sarcoplasmic reticulum in saponin permeabilized skeletal muscle fibres. Pflugers Arch 1998; 436: 104-11
18. Diem K, Lentner C. Scientific Tables, 7th Edn. Macclesfield: Geigy Pharmaceuticals, 1970; 85-6
19. Franks NP, Lieb WR. Temperature dependence of the potency of volatile general anesthetics: Implications for in vitro experiments. Anesthesiology 1996; 84: 716-20
20. Davies DN, Steward A, Allott PR, Mapleson WW. A comparison of arterial and arterialized venous concentrations of halothane. Br J Anaesth 1972; 44: 548-50
21. 2+ release from the sarcoplasmic reticulum of skeletal muscle. Anesthesiology 1999; 91: 179-86
22. Snoeck MM, Gielen MJ, Tangerman A, van Egmond J, Dirksen R. Contractures in skeletal muscle of malignant hyperthermia susceptible patients after in vitro exposure to sevoflurane. Acta Anaesthesiol Scand 2000; 44: 334-7
23. Hopkins P, Halsall JP. In vitro skeletal muscle contracture responses to sevoflurane - a potential diagnostic test for malignant hyperthermia susceptibility? Br J Anaesth 2004; 92: 311P-2P
24. Eckenhoff RG, Johansson JS. On the relevance of 'clinically relevant concentrations' of inhaled anesthetics in in vitro experiments. Anesthesiology 1999; 91: 856-60
25. Strazis KP, Fox AW. Malignant hyperthermia: A review of published cases. Anesth Analg 1993; 77: 297-304
26. Nelson TE, Flewellen EH, Belt MW, Kennamer DL, Winsett OE, Bee DE. Calcium and magnesium content of skeletal muscle. Studies in subjects undergoing diagnostic testing for malignant hyperthermia. Br J Anaesth 1987; 59: 730-4
27. Nadler JL, Malayan S, Luong H, Shaw S, Natarajan RD, Rude RK. Intracellular free magnesium deficiency plays a key role in increased platelet reactivity in type II diabetes mellitus. Diabetes Care 1992; 15: 835-41
28. Haigney MC, Wei S, Kaab S, et al. Loss of cardiac magnesium in experimental heart failure prolongs and destabilizes repolarization in dogs. J Am Coll Cardiol 1998; 31: 701-6
29. Gustafson T, Boman K, Rosenhall L, Sandstrom T, Wester PO. Skeletal muscle magnesium and potassium in asthmatics treated with oral beta 2-agonists. Eur Respir J 1996; 9: 237-40
30. +-pump concentration in skeletal muscle. Acta Physiol Scand 1996; 156: 305-11
31. Lajer H, Bundgaard H, Secher NH, Hansen HH, Kjeldsen K, Daugaard G. Severe intracellular magnesium and potassium depletion in patients after treatment with cisplatin. Br J Cancer 2003; 89: 1633-7
32. Rodman JS. Hypermagnesemia and progression of renal failure. Clin Nephrol 1986; 26: 314
33. Dorman BH, Sade RM, Burnette JS, et al. Magnesium supplementation in the prevention of arrhythmias in pediatric patients undergoing surgery for congenital heart defects. Am Heart J 2000; 139: 522-8
34. Paolisso G, Passariello N, Pizza G, et al. Dietary magnesium supplements improve B-cell response to glucose and arginine in elderly non-insulin dependent diabetic subjects. Acta Endocrinol (Copenh) 1989; 121: 16-20
35. 2+] in malignant hyperthermia susceptible swine. Anesthesiology 1990; 73: 109-17
36. 2+ indicator furaptra in frog skeletal muscle fibers. Biophys J 1993; 64: 223-39